2024
Trends in Incidence and Survival of Patients with Primary Effusion Lymphoma in the United States
Vaughn J, Epperla N. Trends in Incidence and Survival of Patients with Primary Effusion Lymphoma in the United States. Blood 2024, 144: 5119. DOI: 10.1182/blood-2024-211851.Peer-Reviewed Original ResearchSurvival of patientsPrimary effusion lymphomaOverall survivalAnnual percent changeB symptomsAssociated with HIV infectionEffusion lymphomaTreatment of PELPopulation-based cohort study of patientsRelative survivalCohort study of patientsIncidence rateFive-year OSMedian follow-upFive-year RSWorld Health OrganizationPopulation-based cohort studyAge-adjusted incidence ratesCalculate annual percent changesStudy of patientsPatients to clinical trialsTreatment of HIVPeriod of diagnosisFlexible parametric survival modelsDA-EPOCH
2021
Racial disparities in the survival of patients with indolent non‐Hodgkin lymphomas in the United States
Vaughn J, Spies D, Xavier A, Epperla N. Racial disparities in the survival of patients with indolent non‐Hodgkin lymphomas in the United States. American Journal Of Hematology 2021, 96: 816-822. PMID: 33864695, DOI: 10.1002/ajh.26198.Peer-Reviewed Original ResearchConceptsIndolent non-Hodgkin lymphomaSurvival of patientsHighest excess mortality ratesYoung black patientsBlack patientsNon-Hodgkin lymphomaExcess mortality ratesRelative survivalWhite patientsRacial disparitiesMortality rateExcess deathsLymphoplasmacytic lymphoma/Waldenström macroglobulinemiaFlexible parametric survival modelsAmerican Indians/Alaska NativesMarginal zone lymphomaAsian/Pacific IslandersSignificant racial differencesPaucity of dataAdult patientsDisease histologyPrimary outcomeParametric survival modelsMultivariable analysisWaldenström's macroglobulinemiaSurvival of patients with marginal zone lymphoma in the United States: A population‐based cohort study (2000 to 2017)
Vaughn J, Pinheiro L, Olszewski A, Epperla N. Survival of patients with marginal zone lymphoma in the United States: A population‐based cohort study (2000 to 2017). American Journal Of Hematology 2021, 96: e123-e126. PMID: 33476433, DOI: 10.1002/ajh.26103.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCohort StudiesConfounding Factors, EpidemiologicFemaleHumansKaplan-Meier EstimateLymphoma, B-Cell, Marginal ZoneMaleMiddle AgedMortalityPrognosisRituximabSEER ProgramSocial Determinants of HealthUnited StatesYoung AdultConceptsPopulation-based cohort studySurvival of patientsMarginal zone lymphomaCohort studyPatientsLymphoma